MK-3475-04C
A Study of Efficacy and Safety of Sacituzumab Tirumotecan Plus Enfortumab Vedotin With and Without Pembrolizumab in Advanced Urothelial Carcinoma
Active, Not Recruiting
Trial purpose
This study is a substudy being conducted under one pembrolizumab umbrella master study KEYMAKER-U04. The substudy will consist of 2 parts. Part 1 will evaluate the safety and preliminary efficacy of sacituzumab tirumotecan plus enfortumab vedotin (EV). Part 2 will be based on Part 1 results and will evaluate the efficacy, pharmacokinetics, and safety of sacituzumab tirumotecan plus EV in combination with pembrolizumab in participants with advanced urothelial carcinoma.
View full trial information on Clinicaltrials.govNATIONAL TRIAL REFERENCE NUMBER
NCT06483334
When you talk with your doctor or clinical trial team member, please have the national trial reference number available.
Eligibility
Only a qualified healthcare professional can determine if you are eligible to take part in a clinical trial. However, this information may be useful in starting a conversation with your doctor.
Conditions
Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma
Age Range
18+
Sex
Male/Female
Study Details
About the trial
Trial Locations
Locations shown may have changed in some cases. Please call the number listed in the location results to confirm the nearest trial site. Talk with a trial site member for more information.